Table 1.
Characteristics of the patients at ACS event
| Whole cohort | Non-OAP | OAP | Clopidogrel | Prasugrel | Ticagrelor | |
|---|---|---|---|---|---|---|
| Patients with ACS, N (% of total) | 54 416 (100.0) | 27 917 (51.3) | 26 499 (48.7) | 23 977 (44.1) | 917 (1.7) | 1605 (2.9) |
| Age in years, N (% of the group) | ||||||
| ≤65 | 16 284 (29.9) | 5486 (19.7) | 10 798 (40.7) | 9388 (39.2) | 603 (65.8) | 807 (50.3) |
| >65 to ≤75 | 13 088 (24.1) | 5859 (21.0) | 7229 (27.3) | 6505 (27.1) | 230 (25.1) | 494 (30.8) |
| >75 to ≤85 | 15 843 (29.1) | 9373 (33.6) | 6470 (24.4) | 6138 (25.6) | 71 (7.7) | 261 (16.3) |
| >85 | 9201 (16.9) | 7199 (25.8) | 2002 (7.6) | 1946 (8.1) | 13 (1.4) | 43 (2.7) |
| Range, min; max | 18.5; 102.8 | 18.5; 102.8 | 18.6; 99.9 | 18.6; 99.9 | 21.3; 94.7 | 31.0; 94.7 |
| Mean (±SD) | 72.1 (12.8) | 75.9 (12.1) | 68.1 (12.2) | 68.6 (12.1) | 60.4 (11.2) | 64.8 (11.1) |
| Sex, N (% of the group) | ||||||
| Male | 32 772 (60.2) | 14 792 (53.0) | 17 980 (67.9) | 16 114 (67.2) | 715 (78.0) | 1151 (71.7) |
| Female | 21 644 (39.8) | 13 125 (47.0) | 8519 (32.1) | 7863 (32.8) | 202 (22.0) | 454 (28.3) |
| Index event type, N (% of the group) | ||||||
| Unstable angina pectoris | 10 888 (20.0) | 6982 (25.0) | 3906 (14.7) | 3689 (15.4) | 31 (3.4) | 186 (11.6) |
| STEMI | 14 507 (26.7) | 4569 (16.4) | 9938 (37.5) | 8666 (36.1) | 741 (80.8) | 531 (33.1) |
| NSTEMI | 29 021 (53.3) | 16 366 (58.6) | 12 655 (47.8) | 11 622 (48.5) | 145 (15.8) | 888 (55.3) |
| Invasive procedure, N (% of the group) | ||||||
| No | 24 397 (44.8) | 18 747 (67.2) | 5650 (21.3) | 5255 (21.9) | 95 (10.4) | 300 (18.7) |
| Coronary angiography only | 7378 (13.6) | 3821 (13.7) | 3557 (13.4) | 3409 (14.2) | 46 (5.0) | 102 (6.4) |
| PCI | 18 641 (34.3) | 1873 (6.7) | 16 768 (63.3) | 14 799 (61.7) | 775 (84.5) | 1194 (74.4) |
| CABG | 4000 (7.4) | 3476 (12.5) | 524 (2.0) | 514 (2.1) | 1 (0.1) | 9 (0.6) |
| Secondary prevention drugs at discharge, N (% of the group) | ||||||
| ACE inhibitor or ARB | 29 789 (54.7) | 11 989 (42.9) | 17 800 (67.2) | 15 913 (66.4) | 744 (81.1) | 1143 (71.2) |
| β-blocker | 38 353 (70.5) | 16 810 (60.2) | 21 543 (81.3) | 19 475 (81.2) | 816 (89.0) | 1252 (78.0) |
| Statin | 35 444 (65.1) | 13 238 (47.4) | 22 206 (83.8) | 19 935 (83.1) | 847 (92.4) | 1424 (88.7) |
| Number of secondary prevention drugs, N (% of the group) | ||||||
| 0 | 8162 (15.0) | 7083 (25.4) | 1079 (4.1) | 1014 (4.2) | 18 (2.0) | 47 (2.9) |
| 1 | 10 545 (19.4) | 7103 (25.4) | 3442 (13.0) | 3209 (13.4) | 56 (6.1) | 177 (11.0) |
| 2 | 18 003 (33.1) | 8459 (30.3) | 9544 (36.0) | 8746 (36.5) | 216 (23.6) | 582 (36.3) |
| 3 | 17 706 (32.5) | 5272 (18.9) | 12 434 (46.9) | 11 008 (45.9) | 627 (68.4) | 799 (49.8) |
| Median (Q1; Q3) | 2 (1; 3) | 1 (0; 2) | 2 (2; 3) | 2 (2; 3) | 3 (2; 3) | 2 (2; 3) |
| Cohort entry year, N (% of the group) | ||||||
| 2009 | 11 962 (22.0) | 6959 (24.9) | 5003 (18.9) | 5003 (20.9) | 0 (0) | 0 (0) |
| 2010 | 11 039 (20.3) | 6362 (22.8) | 4677 (17.6 | 4616 (19.3) | 61 (6.7) | 0 (0) |
| 2011 | 10 869 (20.0) | 5323 (19.1) | 5546 (20.9) | 5300 (22.1) | 246 (26.8) | 0 (0) |
| 2012 | 10 581 (19.4) | 4857 (17.4) | 5724 (21.6) | 4945 (20.6) | 267 (29.1) | 512 (31.9) |
| 2013 | 9965 (18.3) | 4416 (15.8) | 5549 (20.9) | 4113 (17.2) | 343 (37.4) | 1093 (68.1) |
ACE, angiotensin-converting enzyme; ACS, acute coronary syndrome; ARB, angiotensin receptor blocker; CABG, coronary artery bypass grafting; NSTEMI, non-ST elevation myocardial infarction; OAP, oral antiplatelet; PCI, percutaneous coronary intervention; Q, quartile; STEMI, ST elevation myocardial infarction.